Titel

Merkliste
1 Ergebnisse

Ramucirumab as second-line treatment in Chinese patients wi..:

Guoliang Shao ; Yuxian Bai ; Xianglin Yuan...
http://www.sciencedirect.com/science/article/pii/S2589537022004096. , 2022

Link: https://doi.org/10.1016/j.eclinm.2022.101679

RT Journal
T1 <Title>Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:e806fe3c322947ce9fe7c571dbf725cc&Exemplar=1&LAN=DE
				
A1 Guoliang Shao
A1 Yuxian Bai
A1 Xianglin Yuan
A1 Xiaomin Chen
A1 Shanzhi Gu
A1 Kangsheng Gu
A1 Chunhong Hu
A1 Houjie Liang
A1 Yabing Guo
A1 Jufeng Wang
A1 Chia-Jui Yen
A1 Victor Ho-Fun Lee
A1 Chunxiao Wang
A1 Ryan C. Widau
A1 Wanli Zhang
A1 Junjun Liu
A1 Qiang Zhang
A1 Shukui Qin
PB Elsevier
YR 2022
K1 Ramucirumab
K1 Second-line therapy
K1 Advanced hepatocellular carcinoma
K1 Phase 3 study
K1 China
K1 Medicine (General)
K1 R5-920
JF http://www.sciencedirect.com/science/article/pii/S2589537022004096
LK http://dx.doi.org/https://doi.org/10.1016/j.eclinm.2022.101679
DO https://doi.org/10.1016/j.eclinm.2022.101679
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)